Free Trial Information
BioCentury | Sep 3, 2019
Preclinical News

Insilico, WuXi AppTec unveil one piece of hit-generating AI pipeline

Insilico and WuXi AppTec's Nature Biotechnology study provides initial proof-of-concept for the AI company's de novo small molecule generation platform, but the companies have not yet revealed their methods for taking on orphan targets with...
Read More
BioCentury | Feb 26, 2019
Distillery Therapeutics

Cancer

...Phase II testing for pancreatic and breast cancers and Phase I testing for leukemia. TARGET/MARKER/PATHWAY: Discoidin domain receptor tyrosine kinase 2 (DDR2)...
...CONTACT: Dan Theodorescu, Cedars-Sinai Medical Center, Los Angeles, Calif. email: dan.theodorescu@cshs.org Claire Quang Sprycel, dasatinib (BMS-354825) Cedars-Sinai Medical Center Discoidin domain receptor tyrosine kinase 2 (DDR2) Sarcoma...
Read More
BioCentury | Sep 19, 2018
Distillery Techniques

Chemistry

...same affiliation as above email: luxy2016@jnu.edu.cn Sandi Wong Jinan University Wenzhou Medical University Discoidin domain receptor tyrosine kinase 1 (DDR1) Discoidin domain receptor tyrosine kinase 2 (DDR2) Inflammation...
Read More
BioCentury | Jul 28, 2016
Distillery Therapeutics

Therapeutics: Transmembrane 4 L six family member 1 (TM4SF1); discoidin domain receptor tyrosine kinase 1 (DDR1); signal transducer and activator of transcripti

Cancer INDICATION: Breast cancer Patient sample and mouse studies suggest inhibiting TM4SF1 or its activity could help treat breast cancer. In patients, high levels of TM4SF1 in primary tumor samples were associated with poor metastasis-free...
Read More
BioCentury | Feb 18, 2016
Distillery Therapeutics

Therapeutics: Discoidin domain receptor tyrosine kinase 1 (DDR1); Notch pathway; K-Ras (KRAS)

Cancer INDICATION: Lung cancer Patient sample and mouse studies suggest combining inhibitors of DDR1 and the Notch pathway could help treat KRAS-mutant lung cancer. In 554 tumor samples from patients with lung adenocarcinoma, the presence...
Read More
BioCentury | Jan 21, 2016
Distillery Therapeutics

Therapeutics: Discoidin domain receptor tyrosine kinase 1 (DDR1)

Cancer INDICATION: Cancer Cell culture and mouse studies suggest inhibiting DDR1 could help treat cancers resistant to RG7787 . In an RG7787-resistant human skin cancer cell line, RG7787 combined with a DDR1 inhibitor increased cell death...
Read More
BioCentury | Oct 19, 2015
Clinical News

MGCD516: Interim Phase I data

...patient populations, including non-small cell lung cancer (NSCLC) patients with genetic alterations in RET and discoidin domain receptor tyrosine kinase 2 (DDR2)...
Read More
BioCentury | Dec 11, 2014
Distillery Therapeutics

Indication: Cancer

...Licensing status Publication and contact information Cancer Lung cancer AXL receptor tyrosine kinase (AXL; UFO); discoidin domain receptor tyrosine kinase 2 (DDR2)...
Read More
BioCentury | Sep 15, 2014
Clinical News

MGCD516: Phase I started

...alterations in targets potently inhibited by MGCD516, including neurotrophic tyrosine kinase receptor (TRK), RET and discoidin domain receptor tyrosine kinase 2 (DDR2)...
Read More
BioCentury | Dec 5, 2013
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Hodgkin's lymphoma Discoidin domain receptor tyrosine kinase 1 (DDR1) In vitro studies suggest inhibiting DDR1 could help increase the efficacy of chemotherapeutics in Hodgkin's lymphoma....
Read More
Items per page:
1 - 10 of 17